123 results about "Allantoic fluid" patented technology

The invention relates to a method for producing flu virus according to which:a) immunizing a hen by administering a flu vaccine to the hen,b) triggering embryogenesis in one or more eggs of the immunized hen,c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs,d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, ande) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.

An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation can be achieved by subjecting the virus-debris complex to conditions of increased salt concentrations, e.g., 0.5 M or greater.

The invention provides a single clone antibody aiming at H3N2 dog flu virus HA2 protein, belonging to the technical field of biologics. The single clone antibody is prepared by inoculating an H3N2 dog flu virus Jiangsu separated strain JS / 10 separated in 2010 with SPF chicken embryos of 10 days old, collecting allantoic fluid of which the blood clotting titer is greater than or equal to 6, purifying virus inoculation MDCK cells, performing intracutaneous multipoint injection to inoculate mice, after cell fusion, performing three times of ELISA to detect cell supernate that cell colonies are generated, selecting an anti-H3 type hybridization tumor cell strain mAbD7, and recognizing and identifying the antigen so as to verify that the antibody aims at conservative H2A protein, wherein the neutralizing antibody titer is up to 1:12800, and the antibody subclass is IgG2b. The single clone antibody aiming at H3N2 dog flu virus and HA2 protein, which is provided by the invention, provides an important immunological preparation for treating H3N2 dog flu virus infection and has a potential application prospect.

The invention discloses an anti-tumor biological polysaccharide; the polysaccharide is obtained from chick embryo allantoic fluid and chick embryo through separating and purifying; the invention further discloses a specific purification technology of the polysaccharide, wherein the technology is to extract the biological polysaccharide by a method combined with salting-out and membrane technology. By adopting the technology disclosed by the invention, the purifying purity and the recovering rate of chick embryo allantoic fluid and chick embryo are greatly enhanced; through preclinical pharmacodynamic experiments, the biological polysaccharide has an exact killing ability to transplant human body tumors such as human primary liver cancer and ovarian cancer in nude mice, and can completely remove the transplant human body tumor cells from the nude mice after being fed with enough dosage and enough time. The polysaccharide disclosed by the invention is a biological active material with no toxicity and low side effect and is very safe; in addition, the polysaccharide is wide in drug administration route, simple in production process and high in recovering rate, and thus being a novel anti-tumor drug capable of providing great social benefit and economic benefit.

The invention provides a preparation method for a goose-origin reovirus inactivated vaccine. The preparation method comprises the following steps that a goose embryo is inoculated against reoviruses through an allantoic cavity, dead embryo allantoic fluids or live embryo allantoic fluids are collected within 24-144 h after incubation, and reovirus fluids are obtained; the reovirus fluids are inactivated through formaldehyde, Tween-80 is added to be mixed to serve as a water phase, and white oil, Span-80 and aluminium stearate are mixed to serve as an oil phase; and the water phase is added into the oil phase to be mixed uniformly, and the inactivated vaccine is obtained. According to the preparation method, the prepared goose-origin reovirus inactivated vaccine has high protective effects on a gosling, and is suitable for virus immunity of the gosling.

The invention provides an anti-H7N9 subtype avian influenza virus monoclonal antibody epitope as well as a screening method and application thereof, belonging to the technical field of immunodetection. The screening method comprises the following steps: mixing wild type H7N9 subtype avian influenza virus liquid with a corresponding monoclonal antibody with a neutralizing property for incubation, and inoculating the mixture to an SPF chick embryo, so as to obtain allantoic fluid with a positive hemagglutination titer; and carrying out gradient dilution on the positive allantoic fluid, mixing the positive allantoic fluid with the monoclonal antibody for incubation, inoculating the mixture to the SPF chick embryo, determining a hemagglutination inhibition titer of the monoclonal antibody by selecting the allantoic fluid with the positive hemagglutination titer as an antigen, when the determined hemagglutination inhibition titer is lower than the hemagglutination inhibition titer of a wild type virus by 8log2, determining the positive allantoic fluid as an escape mutant of the wild type H7N9 subtype avian influenza virus, measuring an HA gene sequence of the positive allantoic fluid, and determining the epitope recognized by the monoclonal antibody. By virtue of the method, the specific epitope can be clearly screened; the method is simple, accurate and short in screening period.

The invention relates to a novel medicinal composition for improving organism immune function and resisting tumor to address both the symptoms and root cause, and a preparation method. The medicinal composition comprises the following components: 1,500 milliliters of Newcastle disease virus allantoic fluid with a titer of 1:640, 2 milliliters of neuraminidase, 2 milliliters of nuclease, 1.08 grams of glycoprotein G, 10 grams of galactose, 1.0 milligrams of biotin, 5 grams of fucose, 15 grams of astragalus polysaccharide, 2.0 milligrams of sialidase, 2.0 milligrams of phospholipid, 10 milligrams of uracil, 5 milligrams of Vit C, 4.0 milligrams of cholesterol, 200 milligrams of ATP, 22 milliliters of 10 percent KCl, 3.6 grams of MgSO4.7H2O, and 10 milligrams of prothrombin. The experiments for pharmacodynamics, pharmacology and the like, show that the medicinal composition has good inhibiting and killing effects on mouse transplantable tumor such as Lewis lung carcinoma. Compared with the medicament of the conventional invention, the medicinal composition has more remarkable diffidence in the growth inhibiting effect on the mouse Lewis lung carcinoma. The medicinal composition has obvious effect, and is a novel biological anticancer preparation with good social and economic benefits.

The invention provides a bivalent egg yolk antibody against DVH (duck virus hepatitis) as well as a preparation method and an application of bivalent egg yolk antibody. The bivalent egg yolk antibody contains a DHAV (duck hepatitis A virus)-1 type egg yolk antibody against DVH and a DHAV-3 type egg yolk antibody against DVH. The preparation method comprises steps as follows: (1) a DHAV-1 type strain against DVH and a DHAV-3 type strain against DVH are inoculated with an SPF chick embryo and a susceptible duck embryo respectively, an allantoic fluid is obtained, obtained virus fluids are mixed in proportion and inactivated with formalin, and a vaccine is prepared; (2) laying hens are immunized with the vaccine, sampling is performed after immunization for measuring whether the neutralizing titer of DHAV-1 type and DHAV-3 type antigens and antibodies in hyperimmune egg yolk of chickens is larger than or equal to 1:8192, and later, hyperimmune eggs of the chickens are collected; (3) eggshells of the hyperimmune eggs are disinfected, isovolumetric distilled water is added after the egg yolk is collected, and the mixture is stirred and mixed uniformly and then is subjected to pasteurization at the low temperature; purification with an acidified distilled water method and purification with a caprylic acid method are performed; microfiltration and ultrafiltration are performed. The provided bivalent egg yolk antibody is low in cost and high in titer, DVH caused by DHAV-1 and DHAV-3 can be effectively controlled, and remarkable social benefits can be obtained.

The present invention provides a duck viral hepatitis bivalent yolk antibody and a preparation method thereof, wherein the bivalent yolk antibody comprises a duck viral hepatitis DHAV-1 type antibody and a duck viral hepatitis DHAV-3 type antibody. The preparation method comprises: (1) adopting a duck viral hepatitis DHAV-1 type strain and a duck viral hepatitis DHAV-3 type strain to respectively vaccinate SPF chicken embryo and susceptible duck embryo, harvesting allantoic fluid, mixing the harvested virus liquids according to a certain ratio, carrying out formaldehyde inactivation, and preparing a vaccine; (2) adopting the vaccine to immunize laying hens, sampling after immunization to determine whether the neutralizing titer of the anti-DHAV-1 type antigen antibody and the anti-DHAV-3 type antigen antibody in the chicken hyperimmune egg yolk is more than or equal to 1:8192, and collecting the hyperimmune egg of the chicken; and (3) disinfecting the eggshell of the hyperimmune egg, collecting the egg yolk, adding the equal volume of distilled water, uniformly stirring and mixing, carrying out low temperature pasteurization inactivation, adopting an acidification distilled water method to purify, adopting an octanoic acid method to purify, and carrying out micro-filtration and ultra-filtration. The duck viral hepatitis bivalent yolk antibody has characteristics of low cost and high titer, and can be provided for effectively controlling duck viral hepatitis caused by DHAV-1 and DHAV-3 so as to obtain significant social benefits.